I’ve posted on the issue of publishing trial data in industry publications and conferences previously. There is a code of practice that was conceived in conjunction with FDA and the ASX. The conference this week is more of a finance industry event so don’t expect new data from the MAST trial until January 18th oncology conference. This weeks event doesn’t meet the peer review requirement. I will stand corrected if anyone knows more or can interpret the code differently.
Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-30
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $431.8M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.6¢ | $1.037M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1882949 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 399643 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |